Alzinova AB (publ)
ALZ.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$44.72M
Close$
Share Statistics
| Market cap | $44.72 Million |
|---|---|
| Enterprise Value | $32.21 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.26 |
| Beta | 1.08 |
| Outstanding Shares | 159,152,964 |
Return
| Return on Equity | -15.57% |
|---|---|
| Return on Assets | -14.85% |
| Return on Invested Capital | -16.35% |
Valuation & Multiples
| P/E Ratio | -2.05 |
|---|---|
| PEG | 7.06 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.47 |
| Enterprise Value to EBIT | -1.26 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$30,000
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$21,663
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Alzinova AB (publ)
7 employees
CEO: Tord Labuda Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers respon...